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ABSTRACT
The emergence of oligoclonal bands is associated with a favourable outcome after autologous stem cell transplantation in multiple myeloma. The aim of this study was to determine the prevalence of immunoglobulin oligoclonality in 33 patients with multiple myeloma in complete remission achieved with primary therapy with either cytotoxic agents (n:18; 54.5%) or new induction regimens incorporating novel drugs (n:15; 45.4%). Eleven patients (33.3%) developed oligoclonal bands. In the group treated with novel agents, this oligoclonal immune response was observed in 60% (9/15) of the patients versus in only 11.1% (2/18) of those given cytotoxic therapy (p=0.003). This is the first report showing a different frequency of oligoclonal humoral response in patients in complete remission achieved after conventional cytotoxic therapy versus induction incorporating novel agents. This difference could be due to a higher antitumor effect associated with the use of novel drugs, a strongest immune reconstitution, or both.
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INTRODUCTION
The emergence of an oligoclonal humoral response is a well recognized event after autologous stem cell transplantation in multiple myeloma (MM), which has been associated with a good prognosis, and it is likely due to a more durable immune In the overall series, 11 out of the 33 patients (33.3%) developed an oligoclonal humoral immune response. These abnormal bands observed in the IFE pattern lasted from 2.2 to 55.7 months (median 11.5 months). This relatively short duration contrasts with that observed after ASCT in our previous report 5 , where it lasted from 8 to 112 months. This different duration could be explained because myeloablative treatment with high-dose melphalan followed by stem cell rescue probably results in higher tumor reduction resulting in a more powerful immune reconstitution than induction chemotherapy not followed by ASCT.
DESIGN AND METHODS
The high frequency of oligoclonal humoral response after only induction therapy was unexpected. In the ASCT context, 10% of the patients from the Arkansas group Table 1 .
With treatment with melphalan and prednisone the CR rate was less than 5%. The new regimens MPT (melphalan, prednisone and thalidomide) 9, 10 , MPV (melphalan, prednisone and bortezomib) 11 , MPR (melphalan, prednisone and lenalidomide) 12 or lenalidomide/dexamethasone 13 
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